Celcuity Inc.(CELC)

Biotechnology · Minneapolis, MN

$71.25-2.37 (-3.22%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T22:21:11.683Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:21:11.683Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 71.25
Unrounded diluted TTM EPS · period ending 2026-06-30: -4.29

FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

CELC PE Ratio Metrics

PE RATIO

N/A

CELC Competitors' PE Ratio

CELC

Celcuity Inc.

Current

Market Cap

$3.47B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs CELC

Market Cap

$3.48B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSE

Pulse Biosciences, Inc.

vs CELC

Market Cap

$3.44B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRTC

iRhythm Technologies, Inc.

vs CELC

Market Cap

$3.52B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XENE

Xenon Pharmaceuticals Inc.

vs CELC

Market Cap

$3.54B

PE Ratio

N/A

TTM Avg

45.59

3Y Avg

45.17

5Y Avg

45.17

VCYT

Veracyte, Inc.

vs CELC

Market Cap

$3.56B

PE Ratio

31.89

TTM Avg

68.01

3Y Avg

74.85

5Y Avg

74.85

TNGX

Tango Therapeutics, Inc.

vs CELC

Market Cap

$3.57B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACAD

Acadia Pharmaceuticals Inc.

vs CELC

Market Cap

$3.38B

PE Ratio

8.89

TTM Avg

12.92

3Y Avg

23.68

5Y Avg

23.68

PBLS

Parabilis Medicines, Inc.

vs CELC

Market Cap

$3.36B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VKTX

Viking Therapeutics, Inc.

vs CELC

Market Cap

$3.31B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Celcuity Inc. (CELC)	$3.47B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.48B	N/A	N/A	N/A	N/A
Pulse Biosciences, Inc. (PLSE)vs ›	$3.44B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.52B	N/A	N/A	N/A	N/A
Xenon Pharmaceuticals Inc. (XENE)vs ›	$3.54B	N/A	45.59	45.17	45.17
Veracyte, Inc. (VCYT)vs ›	$3.56B	31.89	68.01	74.85	74.85
Tango Therapeutics, Inc. (TNGX)vs ›	$3.57B	N/A	N/A	N/A	N/A
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.38B	8.89	12.92	23.68	23.68
Parabilis Medicines, Inc. (PBLS)vs ›	$3.36B	N/A	N/A	N/A	N/A
Viking Therapeutics, Inc. (VKTX)vs ›	$3.31B	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$71.25

Forward EPS (Est.)

$-4.98

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

CELC PE Ratio Metrics

CELC Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics